Phase 2 N=15 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Chronic Lymphocytic Leukemia · Leukemia
Primary: Best Response — 20; 3; 3 Participants
Phase 2 N=8 Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
Anemia · Cancer Fatigue · Chronic Lymphocytic Leukemia
Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…
Phase 2 N=105 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Phase 3 N=817 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=17 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Leukemia · Lymphoma
Primary: Participants With Objective Response — 0; 1; 13 Participants
Phase 2 N=49 Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Leukemia · Lymphoma
Primary: Overall Objective Response — 10; 5; 26; 4 Participants
Phase 2 N=10 Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…
Phase 2 N=33 Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Leukemia
Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants
Phase 2 N=23 Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants
Phase 2 N=50 Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Leukemia · Lymphoma
Primary: Overall Response — 11; 23; 4; 5 participants
Phase 2 N=33 Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
Chronic Lymphocytic Leukemia
Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…
Phase 2 N=65 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants
Phase 2 N=30 Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 2 N=60 Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
Leukemia · CLL · Chronic Lymphocytic Leukemia
Primary: Overall Response Rate (ORR) — 39 participants
Phase 2 N=5 A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
Leukaemia, Lymphoblastic
Primary: Number of Participants With a Best Response of Either Complete Remission (CR), Nodular Partial Remission (nPR), Complete Remission-incomplete (CRi) or Partial Remission…
Phase 2 N=132 Safety of PCI-32765 in Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants
Phase 2 N=102 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants
Phase 2 N=15 LMB-2 to Treat Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Phase 2 N=43 Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Responders (Complete and Partial Response) — 8; 18 participants
Phase 2 N=45 Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
Primary: Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months — 68.9 percentage of…
Phase 2 N=33 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma
Primary: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen — 0; 5; 28 participants
Phase 2 N=39 Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Response Rate — 22; 2; 8; 4 participants
Phase 2 N=60 CFAR Study in Patients With Chronic Lymphocytic Leukemia
Leukemia · Chronic Lymphocytic Leukemia
Primary: Overall Participant Response — 44; 1; 10 Participants
Phase 2 N=41 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete Response Rate — 10 percentage of participants
Phase 2 N=418 Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: 2-Year Progression Free Survival (PFS) Rate — 0.64; 0.71; 0.74 proportion of participants
Phase 2 N=21 Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 53 percentage of participants